Cardiopathie aux anthracyclines

摘要: Anthracycline-based antineoplastic therapy is the standard of care for various cancers today and represents a breakthrough in this area. The cardiac toxicity anthracyclines well established. acute form often reversible has no predictive value future. This early does not prevent continuation chemotherapy. Late due to anthracycline leading limiting factor its use. In adults, resembles dilated cardiomyopathy, while children it may be expressed as restrictive cardiomyopathy. discovery modifiable risk factors made possible identify patients at high developing late heart failure. Because left ventricular dysfunction failure develop long after treatment ends, prolonged close follow-up mandatory asymptomatic subjects. Follow-up requires serial echocardiography (M-mode, 2D echo, Doppler, tissue speckle tracking, etc.). Anthracycline-induced cardiomyopathy must treated according guidelines chronic with dysfunction, by angiotensin-converting enzyme (ACE) inhibitors beta-blockers. Lifestyle changes reduce long-term risk. Close collaboration between cardiologists oncologists highly desirable optimizing management these patients.